Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: Updated results in a series of 120 patients

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 4, 2004, Pages 1062-1073

  Lerouge, Delphine ^a   Touboul, Emmanuel ^a   Lefranc, Jean Pierre ^b   Genestie, Catherine ^b   Moureau Zabotto, Laurence ^a   Blondon, Jean ^b  

^a HÔPITAL TENON   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Combined modality therapy; Locally advanced noninflammatory breast cancer; Preoperative radiotherapy

Indexed keywords

ANTIBIOTICS; CHEMOTHERAPY; IRRADIATION; PATIENT TREATMENT; RADIOTHERAPY; TUMORS;

PREOPERATIVE IRRADIATION; PRIMARY CHEMOTHERAPHY;

ONCOLOGY;

ANTHRACYCLINE; ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; NAVELBINE; PIRARUBICIN; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; DISEASE COURSE; DISSECTION; FEMALE; FOLLOW UP; HUMAN; IRRADIATION; LYMPHEDEMA; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; MULTIVARIATE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COBALT RADIOISOTOPES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 3042515171     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.12.034     Document Type: Article

References (51)

1. Calais G., Berger C., Descamps P., et al. Conservative treatment feasability with induction chemotherapy, surgery and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer. 74:1994;1283-1288
2. De Lena M., Zucali R., Viganotti G., et al. Combined chemotherapy- radiotherapy approach in locally advanced (T3b-T4) breast cancer. Cancer Chemother Pharmacol. 1:1978;53-59
3. Jacquillat C., Weill M., Baillet F., et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 66:1990;119-129
4. Schwartz G.F., Birchansky C.A., Komarnicky L., et al. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer. 73:1994;362-369
5. Touboul E., Buffat L., Lefranc J.P., et al. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys. 34:1996;1019-1028
6. Merajver S.D., Weber B.L., Cody R., et al. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience. J Clin Oncol. 15:1997;2873-2881
7. Danforth D.N. Jr, Zujerwski J., O'Shaughnessy J., et al. Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA, B breast cancer. Ann Surg Oncol. 5:1998;150-158
8. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 17:1999;460-469
9. Veronesi U., Bonadonna G., Zurrida S., et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 222:1995;612-618
10. Bonadonna G., Valagussa P., Brambilla C., et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol. 16:1998;93-100
11. Kuerer H.M., Hunt K.K., Newman L.A., et al. Neoadjuvant chemotherapy in women with invasive breast carcinoma: Conceptual basis and fundamental surgical issues. J Am Coll Surg. 190:2000;350-363
12. De Lena M., Varini M., Zucali R., et al. Multimodal treatment for locally advanced breast cancer: Results of chemotherapy-radiotherapy vs chemotherapy-surgery. Cancer Clin Trials. 4:1981;229-236
13. Perloff M., Lesnick G.J., Korzun A., et al. Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinomas: A cancer and leukemia group B study. J Clin Oncol. 6:1988;261-269
14. Pierce L.J., Lippman M., Ben-Baruch N., et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 23:1992;949-960
15. Buchholz T.A., Tucker S.L., Masullo L., et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 20:2001;17-23
16. Buchholz T.A., Katz A., Strom E.A., et al. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 53:2002;880-888
17. Mauriac L., Mac Grogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: A unicentre randomized trial with a 124 months median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBSGS). Ann Oncol. 10:1999;47-52
18. Semiglazov V.F., Topuzov E.E., Bavli J.L., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol. 5:1994;591-595
19. Makris A., Powles T.J., Ashley S.E., et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in breast cancer. Ann Oncol. 9:1998;1179-1184
20. Broët P., Scholl S.M., de la Rochefordière A., et al. Short and long term effects on survival in breast cancer patients treated by primary chemotherapy: An updated analysis of a randomized trial. Breast Cancer Res Treat. 58:1999;151-156
21. Wolmark N., Wang J., Manounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 30:2001;96-102
22. Van der Hage J.A., Van de Velde C.J.H., Julien J.P., et al. Preoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol. 19:2001;4224-4237
23. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. J Clin Oncol. 20:2002;3628-3636
24. Brito R.A., Valero V., Buzdar A.U., et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M. D. Anderson Cancer Center experience. J Clin Oncol. 19:2001;628-633
25. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer. 47:1981;207-214
26. ICRU 1993. Prescribing, recording and reporting photon beam therapy. International Commission on Radiation Units and Measurements Report 50. Washington, DC.; 1993
27. Pierquin B., Owen R., Maylin C., et al. Radical radiation therapy of breast cancer. Int J Radiat Oncol Biol Phys. 6:1980;17-24
28. Pierquin B., Dutreix A., Paine C.H., et al. The Paris system in interstitial radiation therapy. Acta Radiol. 17:1978;33-48
29. Sataloff D.M., Mason B.A., Seinige U.L., et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg. 180:1995;297-304
30. Harris J.R., Levene M.B., Swenson G., et al. Analysis of cosmetic results following primary radiation therapy for stage I and II carcinoma of the breast. Int J Radiat Oncol Biol Phys. 5:1979;257-261
31. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481
32. Mantel N., Haenszel W. Chi-square with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 58:1963;690-700
33. Cox D.R. Regression models and life table. J R Stat Soc. 34:1972;187-220
34. De Matteis A., Nuzzo F., D'Aiuto G., et al. Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: A single-center phase II study. Cancer. 94:2002;895-901
35. Miller K.D., Mc Caskill-Stevens W., Sisk J., et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol. 17:1999;3033-3037
36. Smith I.E., Walsh G., Jones A.L., et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 13:1995;424-429
37. Smith I.C., Hutcheon A.W., Miller I.D., et al. Neoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxel. J Clin Oncol. 20:2002;1456-1466
38. Von Minchwitz G., Costa S.D., Raab G., et al. Dose-dense doxorubicin, docetaxel and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIB study. J Clin Oncol. 19:2001;3506-3515
39. Esserman L., Hylton N., Yassa L., et al. Utility of resonance magnetic imaging in the management of breast cancer: Evidence for improved preoperative staging. J Clin Oncol. 17:1999;110-119
40. Mankoff D.A., Dunwald L.K., Gralow J.R., et al. Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med. 43:2002;500-509
41. Rieber A., Brambs H.J., Gabelmann A., et al. Breast RMI for monitoring response of primary breast cancer to neoadjuvant chemotherapy. Eur Radiol. 12:2002;1711-1719
42. Ellis P., Smith I., Ashley S., et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol. 16:1998;107-114
43. Scholl S.M., Pierga J.Y., Asselain B., et al. Breast tumor response to primary predicts local and distant control as well as survival. Eur J Cancer. 31A:1995;1969-1975
44. Brain E., Garrino C., Misset J.L., et al. Long term prognostic and predictive factors in 107 stage II-III breast cancer patients treated with anthracycline based neoadjuvant chemotherapy. Br J Cancer. 75:1997;1360-1367
45. Pierga J.Y., Mouret E., Dieras V., et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer. 83:2000;1480-1487
46. Chollet P., Amat S., Cure H., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer. 86:2002;1041-1046
47. Chevillard S., Pouillart P., Beldjord C., et al. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer. 77:1996;292-300
48. Remvikos Y., Jouve M., Beuzedoc P., et al. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: A flow cytometry study on fine needle aspirates. Eur J Cancer. 13:1993;1843-1848
49. Manounas E.P. Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies. Semin Oncol. 25:(2 Suppl. 3):1998;31-35
50. Hurley J, Doliny P, Silva O, et al. Neoadjuvant Herceptin/taxotere/ cisplatin in the treatment of locally advanced and inflammatory breast cancer [Abstract]. Proc Am Soc Clin Oncol 2002;21
51. Huang E., Mc Neese M.D., Strom E.A., et al. Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. Int J Radiat Oncol Biol Phys. 53:2002;1225-1233